BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/2/2024 10:44:59 AM | Browse: 568 | Download: 1038
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 88407
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors
Manuscript Source Invited Manuscript
All Author List Mo-Wei Kong, Feng-Di Sun, Zhen-Ying Pei, Li Xu, Ze-Bi Wang, Yan Chen, Shu-Qing Tang, Ting-Fang Yang and Guo-Xiang He
Funding Agency and Grant Number
Corresponding Author Ting-Fang Yang, MD, Doctor, Doctor, Department of Oncology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang, Guiyang 550018, Guizhou Province, China. 672539517@qq.com
Key Words Cardiotoxicity; Gastrointestinal tumors; Risk factors; Fluoropyrimidine; Chest pain
Core Tip This editorial focuses on the occurrence, clinical characteristics, and risk factors of fluoropyrimidine drug-related cardiotoxicity in patients with gastrointestinal tumors. Despite advancements in diagnostic and therapeutic techniques for digestive system tumors, treatment-related cardiotoxicity rates have been increasing, impacting the survival and prognosis of cancer patients. Fluoropyrimidine drugs, widely used in treating malignant tumors, including gastrointestinal tumors, are the second largest class of drugs associated with cardiotoxicity. However, there is often a lack of awareness or understanding regarding their cardiotoxic effects and associated risks.
Publish Date 2024-02-02 09:42
Citation Kong MW, Sun FD, Pei ZY, Xu L, Wang ZB, Chen Y, Tang SQ, Yang TF, He GX. Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors. World J Gastrointest Oncol 2024; 16(2): 251-254
URL https://www.wjgnet.com/1948-5204/full/v16/i2/251.htm
DOI https://dx.doi.org/10.4251/wjgo.v16.i2.251
Full Article (PDF) WJGO-16-251-with-cover.pdf
Full Article (Word) WJGO-16-251.docx